 |
Lee Dong-hoon, president of SK Biopharm (provided = SK Biopharm) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] SK Biopharm announced on the 27th that it has signed a contract with SK Life Science to supply medicines worth 110.3314 billion won.
The contract size is 44.8% of recent sales. The contract period is from this day to September 30th.
This contract is a contract to supply products to SK Life Science, a US subsidiary, for the sale of SK Biopharm's new drug "Cenobamate" (product name: XCOPRI|) in the US market. It is an internal transaction that is not caught by sales based on consolidated financial statements.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
